Philippe Rousselot

Philippe Rousselot, (born 4 September 1945) is a French cinematographer and film director best known for his wide range of work in both European and mainstream American cinema, ranging in genres from drama, to fantasy, to blockbusters. He has collaborated with directors such as Robert Redford, Neil Jordan, Stephen Frears, Tim Burton, David Yates, and Guy Ritchie. He is the recipient of three César Awards, a BAFTA, an Oscar, and is a nominee for the Palme d'Or. Provided by Wikipedia
Showing 1 - 14 results of 14 for search 'Philippe Rousselot', query time: 0.04s Refine Results
  1. 1
    Compte-rendu de Hélène PARENT, Modernes Cicéron, La romanité des orateurs révolutionnaires (1789-1807)

    Compte-rendu de Hélène PARENT, Modernes Cicéron, La romanité des orateurs révolutionnaires (1789-1807) by Philippe Rousselot

    Published 2023-06-01
    Get full text
    Article
  2. 2
    Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

    Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura by Mathilde Chanut, Rym Jaidi, Milena Kohn, Thomas Grange, Clara Brones, Naëlle Lombion, Philippe Rousselot, Thomas Longval

    Published 2022-05-01
    Get full text
    Article
  3. 3
    Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review

    Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review by Solo Traoré, Mehdi Roumila, Pirayeh Eftekhari, Hassan Farhat, Fatiha Merabet, Oumar Guira, Philippe Rousselot, Reza Azarian, Caroline Besson

    Published 2020-11-01
    Get full text
    Article
  4. 4
    Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

    Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review by Jorge E. Cortes, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi K. Kota, Philippe Rousselot, Carlo Gambacorti-Passerini

    Published 2018-12-01
    Get full text
    Article
  5. 5
    AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome

    AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome by Nada Assaf, Christine Lefebvre, Victoria Raggueneau, Geoffroy Guignedoux, Alice Marceau-Renaut, Simon Chevalier, Sylvie Tondeur, Dominique Bories, Riad Benramdane, Philippe Rousselot, Christine Terré

    Published 2022-12-01
    Get full text
    Article
  6. 6
    S106: METABOLIC PLASTICITY REVEALS A TARGETABLE VULNERABILITY IN LEUKEMIA

    S106: METABOLIC PLASTICITY REVEALS A TARGETABLE VULNERABILITY IN LEUKEMIA by Guillaume Andrieu, Mathieu Simonin, Aurélie Cabannes-Hamy, Etienne Lengliné, Ambroise Marçais, Marie-Emilie Dourthe, Alexandre Theron, Nicolas Boissel, Hervé Dombret, Philippe Rousselot, Olivier Hermine, Vahid Asnafi

    Published 2023-08-01
    Get full text
    Article
  7. 7
    DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia

    DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia by Stéphanie Maupetit‐Mehouas, Franck Court, Céline Bourgne, Agnès Guerci‐Bresler, Pascale Cony‐Makhoul, Hyacinthe Johnson, Gabriel Etienne, Philippe Rousselot, Denis Guyotat, Alexandre Janel, Eric Hermet, Sandrine Saugues, Juliette Berger, Philippe Arnaud, Marc G. Berger

    Published 2018-06-01
    Get full text
    Article
  8. 8
    P319: IL7-RECEPTOR EXPRESSION IS FREQUENT IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND PREDICTS SENSITIVITY TO JAK-INHIBITION

    P319: IL7-RECEPTOR EXPRESSION IS FREQUENT IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND PREDICTS SENSITIVITY TO JAK-INHIBITION by Lucien Courtois, Aurélie Cabannes-Hamy, Rathana Kim, Marine Delecourt, Antoine Pinton, Guillaume Charbonnier, Melanie Feroul, Charlotte Smith, Giulia Tueur, Cecile Pivert, Estelle Balducci, Mathieu Simonin, Salvatore Spicuglia, Nicolas Boissel, Guillaume Andrieu, Vahid Asnafi, Philippe Rousselot, Ludovic Lhermitte

    Published 2023-08-01
    Get full text
    Article
  9. 9
    PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY

    PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY by Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel Cook, Philippe Rousselot, David Rizzieri, Jane Liesveld, Pierre Fenaux, Thorsten Braun, Arnaud Pigneux, Pierre Peterlin, Sofia Paul, Nisha Rajagopal, John Carulli, David Roth, Angela Volkert, Tanya Abdul Malak, Michael Kelly, Virginia Klimek, Eytan Stein

    Published 2023-08-01
    Get full text
    Article
  10. 10
    P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB

    P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB by Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Soledad Undurraga, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James Mccloskey, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane Apperley

    Published 2023-08-01
    Get full text
    Article
  11. 11
    S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

    S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL by Elias Jabbour, Hagop Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gomez, Maria Baer, Carlo Gambacorti-Passerini, James Mccloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice Wang, Meliessa Hennessy, Niti Patel, Alexander Vorog, Bingxia Wang, Huilan Yao, Tammie Yeh, Josep Maria Ribera

    Published 2023-08-01
    Get full text
    Article
  12. 12
    Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

    Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia by Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stéphane Bouchet, François-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot

    Published 2022-08-01
    Get full text
    Article
  13. 13
    S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY

    S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY by Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck Emmanuel Nicolini, Henrik Hjorth-Hansen, Antonio Almeida, Jeroen J. W. M. Janssen, Jiri Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson-Strömberg, Joaquín Martinez-Lopez, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Katerina Machova Polakova, Satu Mustjoki, Marc Berger, Andreas Hochhaus, Markus Pfirrmann, Susanne Saussele

    Published 2023-08-01
    Get full text
    Article
  14. 14
    Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

    Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial by Hartmut Döhner, Argiris Symeonidis, Dries Deeren, Judit Demeter, Miguel A. Sanz, Achilles Anagnostopoulos, Jordi Esteve, Walter Fiedler, Kimmo Porkka, Hee-Je Kim, Je-Hwan Lee, Kensuke Usuki, Stefano D'Ardia, Chul Won Jung, Olga Salamero, Heinz-August Horst, Christian Recher, Philippe Rousselot, Irwindeep Sandhu, Koen Theunissen, Felicitas Thol, Konstanze Döhner, Veronica Teleanu, Daniel J. DeAngelo, Tomoki Naoe, Mikkael A. Sekeres, Valerie Belsack, Miaomiao Ge, Tillmann Taube, Oliver G. Ottmann

    Published 2021-08-01
    Get full text
    Article

Search Tools: